Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review

被引:15
|
作者
Wang, Yizhi [1 ]
Zhong, Xi [2 ]
Zhou, Li [1 ]
Lu, Jun [1 ]
Jiang, Bolun [1 ]
Liu, Chengxi [1 ]
Guo, Junchao [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China
[2] China Med Univ, Key Lab Precis Diag & Treatment Gastrointestinal, Dept Surg Oncol & Gen Surg, Minist Educ,Affiliated Hosp 1, Shenyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
基金
中国国家自然科学基金;
关键词
pancreatic ductal adenocarcinoma; biomarkers; umbrella review; prognosis; survival; CARBOHYDRATE ANTIGEN 19-9; TO-LYMPHOCYTE RATIO; DIGESTIVE-SYSTEM; SOLID TUMORS; CANCER STATISTICS; METAANALYSIS; EXPRESSION; SURVIVAL; MARKERS; INFLAMMATION;
D O I
10.3389/fonc.2020.01466
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:Pancreatic ductal adenocarcinoma (PDAC) leads to the majority of cancer-related deaths due to its morbidity with similar mortality. Lack of effective prognostic biomarkers are the main reason for belated post-operative intervention of recurrence which causes high mortality. Numerous systematic reviews and meta-analyses have explored the prognostic value of biomarkers in PDAC so far. In this article, we performed an umbrella review analyzing these studies to provide an overview of associations between prognostic biomarkers and PDAC survival outcome and synthesized these results to guide better clinical practice. Methods:Systematic reviews and meta-analyses investigating the associations between PDAC survival outcomes and prognostic biomarkers were acquired via the PubMed and Embase databases from inception till February 1, 2020. Associations supported by nominally statistically significant results were classified into strong, highly suggestive, suggestive, and weak based on several critical factors such as the statistical significance of summary estimates, the number of events, the estimate of the largest study included, interstudy heterogeneity, small-study effects, 95% predictive interval (PI), excess significance bias, and the results of credibility ceiling sensitivity analyses. Results:We included 41 meta-analyses containing 63 associations between PDAC survival outcomes and prognostic biomarkers. Although, none was supported by strong evidence among these associations, an association between C-reactive protein to albumin ratio (CAR) and PDAC overall survival (OS) and an association between neutrophil-lymphocyte ratio (NLR) and PDAC OS were supported by highly suggestive evidence. Otherwise, the association between lactate dehydrogenase (LDH) and PDAC OS was supported by suggestive evidence. The remaining 60 associations were supported by weak or not suggestive evidence. Conclusion:Associations between CAR or NLR and PDAC OS were supported by highly suggestive evidence. And the association between LDH and PDAC OS was supported by suggestive evidence. Although the methodological quality of the included systematic reviews and meta-analyses which were evaluated by AMSTAR2.0 is generally poor, the identification of the relatively robust prognostic biomarkers of PDAC may guide better post-operative intervention and follow-up to prolong patients' survival.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Biomarkers in pancreatic ductal adenocarcinoma
    Gallego, J.
    Lopez, C.
    Pazo-Cid, R.
    Lopez-Rios, F.
    Carrato, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12) : 1430 - 1437
  • [2] Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence
    Zhou, Cen
    Zhong, Xi
    Song, Yongxi
    Shi, Jinxin
    Wu, Zhonghua
    Guo, Zhexu
    Sun, Jie
    Wang, Zhenning
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [3] Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
    Lindgaard, Sidsel C.
    Maag, Emil
    Sztupinszki, Zsofia
    Chen, Inna M.
    Johansen, Astrid Z.
    Jensen, Benny, V
    Bojesen, Stig E.
    Nielsen, Dorte L.
    Szallasi, Zoltan
    Johansen, Julia S.
    CANCERS, 2022, 14 (13)
  • [4] Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma
    Iuga, Cristina
    Seicean, Andrada
    Iancu, Cornel
    Buiga, Rares
    Sappa, Praveen K.
    Voelker, Uwe
    Hammer, Elke
    PROTEOMICS, 2014, 14 (7-8) : 945 - 955
  • [5] Prognostic Significance of C-reactive protein or Prealbumin in Pancreatic Ductal Adenocarcinoma
    Guo, Yu
    Dou, Yibo
    Ma, Xi
    Li, Zhifei
    Li, Haorui
    Sun, Xugang
    Gao, Chuntao
    Liang, Yuexiang
    Zhao, Tiansuo
    JOURNAL OF SURGICAL RESEARCH, 2025, 306 : 543 - 553
  • [6] microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis
    Frampton, Adam E.
    Krell, Jonathan
    Jamieson, Nigel B.
    Gall, Tamara M. H.
    Giovannetti, Elisa
    Funel, Niccola
    Prado, Mireia Mato
    Krell, Daniel
    Habib, Nagy A.
    Castellano, Leandro
    Jiao, Long R.
    Stebbing, Justin
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (11) : 1389 - 1404
  • [7] Prognostic biomarkers related to tumoral microenvironment in pancreatic ductal adenocarcinoma: a systematic review
    Constantin, Alina Liliana
    Cazacu, Irina Mihaela
    Stroescu, Cezar
    Copaescu, Catalin
    Saftoiu, Adrian
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2021, 62 (03) : 671 - 678
  • [8] Prognostic value of microRNA-21 in pancreatic ductal adenocarcinoma: a meta-analysis
    Hu, Geng-yuan
    Tao, Feng
    Wang, Wei
    Ji, Ke-wei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [9] Expression, clinicopathologic, and prognostic significance of MMP15 in operable pancreatic ductal adenocarcinoma
    Liu, Wen-Jing
    Liu, Jian-Zhou
    Zhou, Wei-Xun
    Zhou, Li
    Guo, Jun-Chao
    JOURNAL OF PANCREATOLOGY, 2023, 6 (03) : 96 - 100
  • [10] Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
    McGuigan, Andrew J.
    Coleman, Helen G.
    McCain, R. Stephen
    Kelly, Paul J.
    Johnston, David, I
    Taylor, Mark A.
    Turkington, Richard C.
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2021, 7 (02) : 99 - 112